BridgeBio Oncology Therapeutics Inc. (BBOT) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -1181.7%, revenue growth 34.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $11.34M |
| Revenue (TTM) | $0.0B |
| Net Margin | -1181.7% |
| Operating Margin (TTM) | -1747.9% |
| Revenue Growth (YoY) | 34.2% |
| EPS Growth (YoY) | -99.9% |
| FCF Growth (YoY) | 13986.8% |
| Price / Book | 2.25 |
| Price / Sales | 48.91 |
| FCF Yield | -30.8% |
| Altman Z-Score | 10.60 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
BBOT overview · BBOT earnings · BBOT KPIs · BBOT documents · BBOT ownership · BBOT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.